SEC Form 4 · accession 0001144204-18-015059
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
June Sherie Almenoff
Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 16, 2018 · 6:06 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 15, 2018 | A | 5,700 | $3.50 | A | 5,700 | I | By Meadowlark Management LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.